Latest Conference Articles

January 25th 2024, 6:30pm

Genitourinary Cancers Symposium (ASCO GU)

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

January 25th 2024, 5:57pm

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

January 22nd 2024, 2:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

January 20th 2024, 7:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Minimal residual disease detection by ctDNA was predictive and prognostic of disease recurrence and response to adjuvant chemotherapy in patients with CRC.

January 20th 2024, 6:41pm

Gastrointestinal Cancers Symposium (ASCO GI)

Nivolumab/ipilimumab reduced the risk of disease progression or death vs chemotherapy in previously untreated patients with metastatic colorectal cancer.

January 20th 2024, 6:14pm

Gastrointestinal Cancers Symposium (ASCO GI)

Daneng Li, MD, discusses a study utilizing of ADG126 in combination with pembrolizumab for patients with microsatellite stable colorectal cancer.

January 20th 2024, 6:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

January 20th 2024, 6:06pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.

January 20th 2024, 5:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.

January 20th 2024, 5:38pm

Gastrointestinal Cancers Symposium (ASCO GI)

DKN-01/bevacizumab/chemotherapy had a tolerable safety profile and showcased clinical activity in patients with microsatellite stable colorectal cancer.

January 20th 2024, 5:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Neoadjuvant botensilimab/balstilimab led to robust responses in both patients with resectable mismatch repair–proficient and –deficient colorectal cancer.

January 20th 2024, 5:14pm

Gastrointestinal Cancers Symposium (ASCO GI)

An improvement in quality-adjusted survival benefit was observed with fruquintinib/BSC vs BSC alone in patients with mCRC enrolled in the FRESCO study.

January 20th 2024, 4:56pm

Gastrointestinal Cancers Symposium (ASCO GI)

Larotrectinib led to long-lasting responses, encouraging survival, and a favorable safety profile in TRK fusion-positive gastrointestinal cancers.

January 20th 2024, 4:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

January 20th 2024, 4:16pm

Gastrointestinal Cancers Symposium (ASCO GI)

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

January 20th 2024, 3:42pm

Gastrointestinal Cancers Symposium (ASCO GI)

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

January 20th 2024, 2:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.

January 19th 2024, 11:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.

January 19th 2024, 10:12pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.

January 19th 2024, 9:55pm

Gastrointestinal Cancers Symposium (ASCO GI)

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.